The Use of Beat-to-Beat Electrocardiogram Analysis to Distinguish QT/QTc Interval Changes Caused by Moxifloxacin From Those Caused by Vardenafil

iCardiac Technologies, Rochester, New York, USA.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.9). 09/2011; 90(3):449-54. DOI: 10.1038/clpt.2011.139
Source: PubMed


QT correction factors (QTc) can cause errors in the interpretation of drug effects on cardiac repolarization because they do not adequately differentiate changes when heart rate or autonomic state deviates from the baseline QT/RR interval relationship. The purpose of our study was to determine whether the new method of QT interval dynamic beat-to-beat (QTbtb) analysis could better discriminate between impaired repolarization caused by moxifloxacin and normal autonomic changes induced by subtle reflex tachycardia after vardenafil. Moxifloxacin produced maximum mean increases of 13-14 ms in QTbtb, QTcF, and QTcI after 4 h. After vardenafil administration, a 10-ms effect could be excluded at all time points with QTbtb but not with QTcF or QTcI. Subset analysis of the vardenafil upper pharmacokinetic quartile showed that the upper bound of QTcF and QTcI was >10 ms, whereas that of QTbtb was <8 ms. This study demonstrated that newer methods of electrocardiogram (ECG) analysis can differentiate changes in the QT interval to improve identification of proarrhythmia risk.

22 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vardenafil orodispersible tablet (ODT) is a supralingual formulation of vardenafil that is available for the on-demand treatment of erectile dysfunction. The pharmacokinetics of vardenafil ODT are not equivalent to those of the vardenafil film-coated tablet in that the ODT formulation provides consistently greater vardenafil systemic exposure. Therefore, the two formulations are not interchangeable. The efficacy of on-demand vardenafil ODT 10 mg was established in the POTENT I and II studies, which were 6-week, randomized, double-blind, multinational trials in men with erectile dysfunction of at least 6 months duration. In both trials, vardenafil ODT improved erectile function significantly more than placebo, as indicated by International Index of Erectile Function-Erectile Function subscale scores at week 12 and overall erection success rates during treatment according to responses to questions 2 and 3 of the Sexual Encounter Profile (coprimary endpoints). In a pooled analysis of both trials, vardenafil ODT improved erectile function regardless of age, severity of erectile dysfunction at baseline or the presence or absence of underlying medical conditions. Vardenafil ODT was generally well tolerated in clinical trials, including in men aged ≥65 years, and adverse events were mostly mild or moderate in severity.
    Drugs 01/2012; 72(1):87-98. DOI:10.2165/11208270-000000000-00000 · 4.34 Impact Factor
  • Source
    Clinical Pharmacology &#38 Therapeutics 02/2012; 91(4):580; author reply 580-1. DOI:10.1038/clpt.2011.294 · 7.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ICH E14 guidance for the clinical evaluation of QT/QTc interval prolongation requires almost all new drugs to undergo a dedicated clinical study, primarily in healthy volunteers, the so-called 'thorough QT/QTc (TQT) study'. Since 2005, when the E14 guidance was implemented in USA and Europe, close to 400 TQT studies have been conducted. In February 2012, the CSRC held a think tank meeting at FDA’s White Oak campus to discuss whether 'QT assessment' can be performed as part of routine Phase 1 studies. Based on these discussions, a group of experts convened to discuss how to improve the confidence in QT data from early clinical studies, e.g. the First-Time-in-Human trial, through collection of serial ECGs and PK samples and the use of exposure response analysis. Recommendations are given on how to design such 'Early ECG assessment' and the limitation of not having a pharmacological positive control in these studies is discussed. A research path is identified towards collecting evidence to replace or provide an alternative to the dedicated TQT study.
    American Heart Journal 09/2014; 168(3). DOI:10.1016/j.ahj.2014.06.003 · 4.46 Impact Factor